CHU Morvan Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01443065
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Institut de Cancérologie, CHRU Brest, Hôpital Morvan

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Esophageal Neoplasms (Phase 2)

Lung Neoplasms (Phase 3)

Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 10